{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:53:23Z","timestamp":1773874403759,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Brandenburg CAMPUS GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Alcohol use disorder (AUD) is a mental disorder with a high prevalence and is one of the most common diagnoses requiring inpatient treatment. For the pharmacological management of withdrawal and detoxification, tranquilizing and anticonvulsant drugs, as well as symptom-triggered therapy, are recommended. In this study, we investigated the use of psychotropic drugs in the inpatient treatment of patients with AUD or acute intoxication by analyzing data from the\n                    <jats:italic>Drug Safety Program in Psychiatry<\/jats:italic>\n                    (German: Arzneimittelsicherheit in der Psychiatrie; AMSP). Patients were classified according to the ICD-10 code F10. The study included 10,332 patients treated for AUD or acute intoxication in participating hospitals between 2000 and 2016. The most frequently used drug classes were antidepressant (31.2%), antipsychotic (29.7%), anticonvulsant (26.4%) and tranquilizing drugs (24.3%), among which benzodiazepines were the most commonly used (23.6%). The most common drugs were carbamazepine (11.1%), diazepam (10.1%), mirtazapine (8.5%) and oxazepam (8.2%). Treatment patterns varied depending on sex and the presence of additional psychiatric diagnosis, such as depressive disorder. During the observation period, the use of antidepressant and antipsychotic drugs increased and the use of tranquilizing drugs doubled, while the use of clomethiazole declined. These findings underscore the need for greater attention to managing comorbidities. However, we also observed a high utilization of non-benzodiazepine sedating drugs\u2014such as trazodone, mirtazapine and quetiapine\u2014even though there is insufficient evidence to support their use in this context. Further research is warranted.\n                  <\/jats:p>","DOI":"10.1007\/s00702-025-03012-z","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T04:45:51Z","timestamp":1756961151000},"page":"547-560","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacotherapy for psychiatric inpatients with alcohol use disorder or acute intoxication: results from an observational pharmacovigilance program\u2014status and changes between 2000 and 2016"],"prefix":"10.1007","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9615-824X","authenticated-orcid":false,"given":"Beatrice","family":"Haack","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Engel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Pauwels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sermin","family":"Toto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Bleich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renate","family":"Grohmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Heinze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Zolk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phileas","family":"Proskynitopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timo","family":"Greiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"issue":"2","key":"3012_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00228-010-0933-z","volume":"67","author":"K Andersson Sundell","year":"2011","unstructured":"Andersson Sundell K, Gissler M, Petzold M, Waern M (2011) Antidepressant utilization patterns and mortality in Swedish men and women aged 20\u201334 years. Eur J Clin Pharmacol 67(2):169\u2013178. https:\/\/doi.org\/10.1007\/s00228-010-0933-z","journal-title":"Eur J Clin Pharmacol"},{"key":"3012_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ejim.2022.05.016","volume":"103","author":"M Antonelli","year":"2022","unstructured":"Antonelli M, Sestito L, Tarli C, Addolorato G (2022) Perspectives on the pharmacological management of alcohol use disorder: are the approved medications effective? Eur J Intern Med 103:13\u201322. https:\/\/doi.org\/10.1016\/j.ejim.2022.05.016","journal-title":"Eur J Intern Med"},{"key":"3012_CR3","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2016.0301","author":"A Batra","year":"2016","unstructured":"Batra A, M\u00fcller CA, Mann K, Heinz A (2016) Alcohol dependence and harmful use of alcohol: diagnosis and treatment options. Dtsch Arztebl Int. https:\/\/doi.org\/10.3238\/arztebl.2016.0301","journal-title":"Dtsch Arztebl Int"},{"issue":"6","key":"3012_CR4","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.euroneuro.2015.03.017","volume":"25","author":"R Bridler","year":"2015","unstructured":"Bridler R, H\u00e4berle A, M\u00fcller ST, Cattapan K, Grohmann R, Toto S, Kasper S, Greil W (2015) Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: a comparison with other psychiatric disorders. Eur Neuropsychopharmacol 25(6):763\u2013772. https:\/\/doi.org\/10.1016\/j.euroneuro.2015.03.017","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"3012_CR5","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s40265-021-01670-3","volume":"82","author":"EM Burnette","year":"2022","unstructured":"Burnette EM, Nieto SJ, Grodin EN, Meredith LR, Hurley B, Miotto K, Gillis AJ, Ray LA (2022) Novel agents for the pharmacological treatment of alcohol use disorder. Drugs 82(3):251\u2013274. https:\/\/doi.org\/10.1007\/s40265-021-01670-3","journal-title":"Drugs"},{"issue":"1","key":"3012_CR6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/JCP.0000000000000814","volume":"38","author":"S Chiappini","year":"2018","unstructured":"Chiappini S, Schifano F (2018) Is there a potential of misuse for quetiapine?: Literature review and analysis of the European medicines agency\/European medicines agency adverse drug reactions\u2019 database. J Clin Psychopharmacol 38(1):72\u201379. https:\/\/doi.org\/10.1097\/JCP.0000000000000814","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"3012_CR7","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1177\/0269881115581093","volume":"29","author":"A Cleare","year":"2015","unstructured":"Cleare A, Pariante CM, Young AH, Anderson IM, Christmas D, Cowen PJ, Dickens C, Ferrier IN, Geddes J, Gilbody S, Haddad PM, Katona C, Lewis G, Malizia A, McAllister-Williams RH, Ramchandani P, Scott J, Taylor D, Uher R, Members of the Consensus Meeting (2015) Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British association for psychopharmacology guidelines. J Psychopharmacol 29(5):459\u2013525. https:\/\/doi.org\/10.1177\/0269881115581093","journal-title":"J Psychopharmacol"},{"key":"3012_CR8","doi-asserted-by":"publisher","unstructured":"Deutsche Gesellschaft F\u00fcr Psychiatrie, P. U. N. (DGPPN), \u00c4rztliches Zentrum F\u00fcr Qualit\u00e4t In Der Medizin (\u00c4ZQ) (2017) S3-Leitlinie\/Nationale VersorgungsLeitlinie Unipolare Depression\u2014Kurzfassung, 2. Auflage [text\/pdf]. Deutsche Gesellschaft f\u00fcr Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN); Bundes\u00e4rztekammer (B\u00c4K); Kassen\u00e4rztliche Bundesvereinigung (KBV); Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). https:\/\/doi.org\/10.6101\/AZQ\/000366","DOI":"10.6101\/AZQ\/000366"},{"key":"3012_CR9","unstructured":"DHS Jahrbuch Sucht 2022 (1. Auflage) (2022) Pabst Science Publishers"},{"issue":"6","key":"3012_CR10","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1111\/add.12875","volume":"110","author":"K Donoghue","year":"2015","unstructured":"Donoghue K, Elzerbi C, Saunders R, Whittington C, Pilling S, Drummond C (2015) The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis. Addiction 110(6):920\u2013930. https:\/\/doi.org\/10.1111\/add.12875","journal-title":"Addiction"},{"key":"3012_CR11","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1007\/978-3-642-46521-5_95","volume-title":"Kardiovaskul\u00e4re Erkrankungen und Nervensystem Neurotoxikologie Probleme des Hirntodes","author":"A Engelhardt","year":"1985","unstructured":"Engelhardt A, Neund\u00f6rfer B, Claus D, Burkowski H (1985) Neurologische Folgeerkrankungen bei chronischem Alkoholismus. In: G\u00e4nshirt H, Berlit P, Haack G (eds) Kardiovaskul\u00e4re Erkrankungen und Nervensystem Neurotoxikologie Probleme des Hirntodes, vol 3. Springer, Berlin, pp 442\u2013445. https:\/\/doi.org\/10.1007\/978-3-642-46521-5_95"},{"issue":"12","key":"3012_CR13","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1111\/j.1468-1331.2010.03153.x","volume":"17","author":"R Galvin","year":"2010","unstructured":"Galvin R, Br\u00e5then G, Ivashynka A, Hillbom M, Tanasescu R, Leone MA, EFNS (2010) EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy. Eur J Neurol 17(12):1408\u20131418. https:\/\/doi.org\/10.1111\/j.1468-1331.2010.03153.x","journal-title":"Eur J Neurol"},{"issue":"6","key":"3012_CR14","doi-asserted-by":"publisher","first-page":"938","DOI":"10.15288\/jsad.2012.73.938","volume":"73","author":"RB Goldstein","year":"2012","unstructured":"Goldstein RB, Dawson DA, Chou SP, Grant BF (2012) Sex differences in prevalence and comorbidity of alcohol and drug use disorders: results from wave 2 of the national epidemiologic survey on alcohol and related conditions. J Stud Alcohol Drugs 73(6):938\u2013950. https:\/\/doi.org\/10.15288\/jsad.2012.73.938","journal-title":"J Stud Alcohol Drugs"},{"issue":"10","key":"3012_CR15","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1111\/acer.12529","volume":"38","author":"CM Goodson","year":"2014","unstructured":"Goodson CM, Clark BJ, Douglas IS (2014) Predictors of severe alcohol withdrawal syndrome: a systematic review and meta-analysis. Alcohol Clin Exp Res 38(10):2664\u20132677. https:\/\/doi.org\/10.1111\/acer.12529","journal-title":"Alcohol Clin Exp Res"},{"issue":"8","key":"3012_CR16","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1001\/archpsyc.61.8.807","volume":"61","author":"BF Grant","year":"2004","unstructured":"Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W, Pickering RP, Kaplan K (2004) Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry 61(8):807. https:\/\/doi.org\/10.1001\/archpsyc.61.8.807","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"3012_CR17","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00406-019-01058-1","volume":"270","author":"T Greiner","year":"2020","unstructured":"Greiner T, Haack B, Toto S, Bleich S, Grohmann R, Faltraco F, Heinze M, Schneider M (2020) Pharmacotherapy of psychiatric inpatients with adjustment disorder: current status and changes between 2000 and 2016. Eur Arch Psychiatry Clin Neurosci 270(1):107\u2013117. https:\/\/doi.org\/10.1007\/s00406-019-01058-1","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"Suppl 1","key":"3012_CR18","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1055\/s-2004-815505","volume":"37","author":"R Grohmann","year":"2004","unstructured":"Grohmann R, Engel RR, R\u00fcther E, Hippius H (2004) The AMSP drug safety program: methods and global results. Pharmacopsychiatry 37(Suppl 1):S4-11. https:\/\/doi.org\/10.1055\/s-2004-815505","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"3012_CR19","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/add.15147","volume":"116","author":"PS Haber","year":"2021","unstructured":"Haber PS, Kortt NC (2021) Alcohol use disorder and the gut. Addiction 116(3):658\u2013667. https:\/\/doi.org\/10.1111\/add.15147","journal-title":"Addiction"},{"issue":"4","key":"3012_CR20","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S1521-6918(03)00030-1","volume":"17","author":"A Heinz","year":"2003","unstructured":"Heinz A, Wilwer M, Mann K (2003) Therapy and supportive care of alcoholics: guidelines for practitioners. Best Pract Res Clin Gastroenterol 17(4):695\u2013708. https:\/\/doi.org\/10.1016\/S1521-6918(03)00030-1","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"4","key":"3012_CR21","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.pop.2017.07.001","volume":"44","author":"R Kellerman","year":"2017","unstructured":"Kellerman R, Kintanar T (2017) Gastroesophageal reflux disease. Prim Care Clin off Pract 44(4):561\u2013573. https:\/\/doi.org\/10.1016\/j.pop.2017.07.001","journal-title":"Prim Care Clin off Pract"},{"key":"3012_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-63677-0","volume-title":"S3-Leitlinie Screening, Diagnose und Behandlung alkoholbezogener St\u00f6rungen","year":"2020","unstructured":"Kiefer F, Hoffmann S, Petersen KU, Batra A (eds) (2020) S3-Leitlinie Screening, Diagnose und Behandlung alkoholbezogener St\u00f6rungen. Springer, Berlin. https:\/\/doi.org\/10.1007\/978-3-662-63677-0"},{"issue":"4","key":"3012_CR23","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1159\/000522335","volume":"28","author":"F Kiefer","year":"2022","unstructured":"Kiefer F, Batra A, Petersen KU, Ardern IS, Tananska D, Bischof G, Funke W, Lindenmeyer J, Mueller S, Preuss UW, Sch\u00e4fer M, Thomasius R, Veltrup C, Weissinger V, Wodarz N, Wurst FM, Guideline Group AUD, Hoffmann S (2022) German guidelines on screening, diagnosis, and treatment of alcohol use disorders: update 2021. Eur Addict Res 28(4):309\u2013322. https:\/\/doi.org\/10.1159\/000522335","journal-title":"Eur Addict Res"},{"issue":"1","key":"3012_CR24","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41386-019-0446-0","volume":"45","author":"GF Koob","year":"2020","unstructured":"Koob GF, Colrain IM (2020) Alcohol use disorder and sleep disturbances: a feed-forward allostatic framework. Neuropsychopharmacology 45(1):141\u2013165. https:\/\/doi.org\/10.1038\/s41386-019-0446-0","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"3012_CR25","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1176\/appi.ajp.20230488","volume":"180","author":"HR Kranzler","year":"2023","unstructured":"Kranzler HR (2023) Overview of alcohol use disorder. Am J Psychiatry 180(8):565\u2013572. https:\/\/doi.org\/10.1176\/appi.ajp.20230488","journal-title":"Am J Psychiatry"},{"issue":"8","key":"3012_CR26","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/jama.2018.11406","volume":"320","author":"HR Kranzler","year":"2018","unstructured":"Kranzler HR, Soyka M (2018) Diagnosis and pharmacotherapy of alcohol use disorder: a review. JAMA 320(8):815. https:\/\/doi.org\/10.1001\/jama.2018.11406","journal-title":"JAMA"},{"issue":"Suppl 1","key":"3012_CR27","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.1093\/schbul\/sbv167","volume":"42","author":"S Leucht","year":"2016","unstructured":"Leucht S, Samara M, Heres S, Davis JM (2016) Dose equivalents for antipsychotic drugs: the DDD method. Schizophr Bull 42(Suppl 1):S90-94. https:\/\/doi.org\/10.1093\/schbul\/sbv167","journal-title":"Schizophr Bull"},{"issue":"5 Supp B","key":"3012_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18553\/jmcp.2012.18.S5-B.1","volume":"18","author":"AR Maher","year":"2012","unstructured":"Maher AR, Theodore G (2012) Summary of the comparative effectiveness review on off-label use of atypical antipsychotics. J Manag Care Pharm 18(5 Supp B):1\u201320. https:\/\/doi.org\/10.18553\/jmcp.2012.18.S5-B.1","journal-title":"J Manag Care Pharm"},{"issue":"1","key":"3012_CR29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jsat.2014.07.006","volume":"48","author":"T Malekshahi","year":"2015","unstructured":"Malekshahi T, Tioleco N, Ahmed N, Campbell ANC, Haller D (2015) Misuse of atypical antipsychotics in conjunction with alcohol and other drugs of abuse. J Subst Abuse Treat 48(1):8\u201312. https:\/\/doi.org\/10.1016\/j.jsat.2014.07.006","journal-title":"J Subst Abuse Treat"},{"issue":"9","key":"3012_CR30","first-page":"589","volume":"88","author":"HL Muncie","year":"2013","unstructured":"Muncie HL, Yasinian Y, Oge\u2019 L (2013) Outpatient management of alcohol withdrawal syndrome. Am Fam Physician 88(9):589\u2013595","journal-title":"Am Fam Physician"},{"issue":"3","key":"3012_CR31","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1024\/suc.2003.49.3.147","volume":"49","author":"G Mundle","year":"2003","unstructured":"Mundle G, Banger M, Mugele B, Stetter F, Soyka M, Veltrup C, Schmidt G, L. (2003) AWMF-Behandlungsleitlinie: Akutbehandlung alkoholbezogener St\u00f6rungen. SUCHT 49(3):147\u2013167. https:\/\/doi.org\/10.1024\/suc.2003.49.3.147","journal-title":"SUCHT"},{"key":"3012_CR32","unstructured":"NICE UK (2011) Alcohol-use disorders: diagnosis, assessment and management of harmful drinking (high-risk drinking) and alcohol dependence | Guidance | NICE. NICE. https:\/\/www.nice.org.uk\/guidance\/cg115"},{"key":"3012_CR33","doi-asserted-by":"publisher","first-page":"CD005063.pub2","DOI":"10.1002\/14651858.CD005063.pub2","volume-title":"Cochrane database of systematic reviews","author":"C Ntais","year":"2005","unstructured":"Ntais C, Pakos E, Kyzas P, Ioannidis JP (2005) Benzodiazepines for alcohol withdrawal. In: TheCochrane Collaboration (ed) Cochrane database of systematic reviews. John Wiley & Sons, Ltd, p CD005063.pub2. https:\/\/doi.org\/10.1002\/14651858.CD005063.pub2"},{"issue":"4","key":"3012_CR34","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1159\/000490046","volume":"24","author":"F Oliva","year":"2018","unstructured":"Oliva F, Nibbio G, Vizzuso P, Jaretti Sodano A, Ostacoli L, Carletto S, Picci RL (2018) Gender differences in anxiety and depression before and after alcohol detoxification: anxiety and depression as gender-related predictors of relapse. Eur Addict Res 24(4):163\u2013172. https:\/\/doi.org\/10.1159\/000490046","journal-title":"Eur Addict Res"},{"issue":"1","key":"3012_CR35","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13722-025-00579-6","volume":"20","author":"P Pauwels","year":"2025","unstructured":"Pauwels P, Haack B, Toto S, Seifert J, Grohmann R, Heinze M, Zolk O, Proskynitopoulos PJ, Schneider M, Greiner T (2025) Pharmacotherapy of psychiatric inpatients with mental and behavioral disorders caused by sedatives or hypnotics (F13): results from an observational pharmacovigilance program between 2000 and 2017. Addict Sci Clin Pract 20(1):51. https:\/\/doi.org\/10.1186\/s13722-025-00579-6","journal-title":"Addict Sci Clin Pract"},{"issue":"48","key":"3012_CR36","first-page":"3103","volume":"173","author":"I Petrov","year":"2011","unstructured":"Petrov I, Krogh J, Nordentoft M (2011) Meta-analysis of pharmacological therapy with acamprosate, naltrexone, and disulfiram\u2014a systematic review. Ugeskr Laeger 173(48):3103\u20133109","journal-title":"Ugeskr Laeger"},{"key":"3012_CR37","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.m2022.0244","author":"C Rauschert","year":"2022","unstructured":"Rauschert C, M\u00f6ckl J, Seitz N-N, Wilms N, Olderbak S, Kraus L (2022) The use of psychoactive substances in Germany. Dtsch Arztebl Int. https:\/\/doi.org\/10.3238\/arztebl.m2022.0244","journal-title":"Dtsch Arztebl Int"},{"issue":"6","key":"3012_CR38","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1111\/add.13757","volume":"112","author":"J Rehm","year":"2017","unstructured":"Rehm J, Gmel GE, Gmel G, Hasan OSM, Imtiaz S, Popova S, Probst C, Roerecke M, Room R, Samokhvalov AV, Shield KD, Shuper PA (2017) The relationship between different dimensions of alcohol use and the burden of disease-an update. Addiction 112(6):968\u20131001. https:\/\/doi.org\/10.1111\/add.13757","journal-title":"Addiction"},{"key":"3012_CR39","unstructured":"Schaller K, Kahnert S, Garcia-Verdugo R, Treede I, Graen L, Ou\u00e9draogo N (with Deutsches Krebsforschungszentrum) (2022) Alkoholatlas Deutschland 2022. Pabst Science Publishers"},{"key":"3012_CR40","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.jad.2020.12.073","volume":"281","author":"J Seifert","year":"2021","unstructured":"Seifert J, Engel RR, Bernegger X, F\u00fchrmann F, Bleich S, St\u00fcbner S, Sieberer M, Greil W, Toto S, Grohmann R (2021a) Time trends in pharmacological treatment of major depressive disorder: results from the AMSP pharmacovigilance program from 2001\u20132017. J Affect Disord 281:547\u2013556. https:\/\/doi.org\/10.1016\/j.jad.2020.12.073","journal-title":"J Affect Disord"},{"issue":"6","key":"3012_CR41","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s00702-021-02349-5","volume":"128","author":"J Seifert","year":"2021","unstructured":"Seifert J, F\u00fchrmann F, Reinhard MA, Engel RR, Bernegger X, Bleich S, St\u00fcbner S, R\u00fcther E, Toto S, Grohmann R, Sieberer M, Greil W (2021b) Sex differences in pharmacological treatment of major depressive disorder: results from the AMSP pharmacovigilance program from 2001 to 2017. J Neural Transm 128(6):827\u2013843. https:\/\/doi.org\/10.1007\/s00702-021-02349-5","journal-title":"J Neural Transm"},{"issue":"8","key":"3012_CR42","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s00702-021-02369-1","volume":"128","author":"J Seifert","year":"2021","unstructured":"Seifert J, Letmaier M, Greiner T, Schneider M, Deest M, Eberlein CK, Bleich S, Grohmann R, Toto S (2021c) Psychotropic drug-induced hyponatremia: results from a drug surveillance program\u2013an update. J Neural Transm 128(8):1249\u20131264. https:\/\/doi.org\/10.1007\/s00702-021-02369-1","journal-title":"J Neural Transm"},{"issue":"12","key":"3012_CR43","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1080\/14656566.2017.1349098","volume":"18","author":"M Soyka","year":"2017","unstructured":"Soyka M, M\u00fcller CA (2017) Pharmacotherapy of alcoholism\u2014an update on approved and off-label medications. Expert Opin Pharmacother 18(12):1187\u20131199. https:\/\/doi.org\/10.1080\/14656566.2017.1349098","journal-title":"Expert Opin Pharmacother"},{"issue":"7","key":"3012_CR44","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00406-006-0644-8","volume":"256","author":"M Soyka","year":"2006","unstructured":"Soyka M, Schmidt P, Franz M, Barth T, De Groot M, Kienast T, Reinert T, Richter C, Sander G (2006) Treatment of alcohol withdrawal syndrome with a combination of tiapride\/carbamazepine: results of a pooled analysis in 540 patients. Eur Arch Psychiatry Clin Neurosci 256(7):395\u2013401. https:\/\/doi.org\/10.1007\/s00406-006-0644-8","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"3012_CR45","doi-asserted-by":"publisher","unstructured":"United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Center for Behavioral Health Statistics and Quality. National Survey on Drug Use and Health, 2012. Inter-university Consortium for Political and Social Research [distributor], 2015-11-23. https:\/\/doi.org\/10.3886\/ICPSR34933.v3","DOI":"10.3886\/ICPSR34933.v3"},{"key":"3012_CR46","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/B978-0-12-801284-0.00011-7","volume-title":"International review of neurobiology","author":"G Szabo","year":"2014","unstructured":"Szabo G, Lippai D (2014) Converging actions of alcohol on liver and brain immune signaling. International review of neurobiology, vol 118. Elsevier, pp 359\u2013380. https:\/\/doi.org\/10.1016\/B978-0-12-801284-0.00011-7"},{"key":"3012_CR47","doi-asserted-by":"publisher","first-page":"1266424","DOI":"10.3389\/fpsyt.2023.1266424","volume":"14","author":"H Unlu","year":"2023","unstructured":"Unlu H, Macaron MM, Ayraler Taner H, Kaba D, Akin Sari B, Schneekloth TD, Leggio L, Abulseoud OA (2023) Sex difference in alcohol withdrawal syndrome: a scoping review of clinical studies. Front Psychiatry 14:1266424. https:\/\/doi.org\/10.3389\/fpsyt.2023.1266424","journal-title":"Front Psychiatry"},{"issue":"45","key":"3012_CR48","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1055\/s-0034-1387353","volume":"139","author":"K Van Der Linde","year":"2014","unstructured":"Van Der Linde K, Wasem J, Lux G (2014) Sekund\u00e4rdatenanalyse der Pr\u00e4valenz der Alkoholabh\u00e4ngigkeit (F10.2) in Deutschland. DMW Deutsche Medizinische Wochenschrift 139(45):2285\u20132289. https:\/\/doi.org\/10.1055\/s-0034-1387353","journal-title":"DMW Deutsche Medizinische Wochenschrift"},{"issue":"2","key":"3012_CR49","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1080\/10826084.2019.1668013","volume":"55","author":"AE Vento","year":"2020","unstructured":"Vento AE, Kotzalidis GD, Cacciotti M, Papanti GD, Orsolini L, Rapinesi C, Savoja V, Calabr\u00f2 G, Del Casale A, Piacentino D, Caloro M, Girardi P, Schifano F (2020) Quetiapine abuse fourteen years later: where are we now? A systematic review. Subst Use Misuse 55(2):304\u2013313. https:\/\/doi.org\/10.1080\/10826084.2019.1668013","journal-title":"Subst Use Misuse"},{"key":"3012_CR50","doi-asserted-by":"publisher","DOI":"10.1007\/3-540-30986-1","volume-title":"Therapielexikon psychiatrie, psychosomatik, psychotherapie","year":"2006","unstructured":"Zaudig M, Trautmann RD (eds) (2006) Therapielexikon psychiatrie, psychosomatik, psychotherapie. Springer-Verlag. https:\/\/doi.org\/10.1007\/3-540-30986-1"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-03012-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-025-03012-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-03012-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T15:14:34Z","timestamp":1773846874000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-025-03012-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["3012"],"URL":"https:\/\/doi.org\/10.1007\/s00702-025-03012-z","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Financial interests: ST is a member of the advisory board for Otsuka and Janssen-Cilag and has received speaker honoraria from Janssen-Cilag, Lundbeck\/Otsuka, Recordati Pharma GmbH, ROVI GmbH and Servier. JS took part in two educational events sponsored by Otsuka\/Lundbeck. The research presented in this manuscript did not receive any specific grants or funding. The AMSP drug safety project is facilitated by nonprofit associations in Germany, Austria, and Switzerland. The AMSP project has been supported with unrestricted educational and research grants since 1993 by the following companies: German companies: Abbott GmbH & Co. KG, AstraZeneca GmbH, Aventis Pharma Deutschland GmbH GE\u2013O\/R\/N, Bayer Vital GmbH, Boehringer Mannheim GmbH, Bristol-Myers-Squibb, Ciba Geigy GmbH, Desitin Arzneimittel GmbH, Duphar Pharma GmbH & Co. KG, Eisai GmbH, Esparma GmbH Arzneimittel, GlaxoSmithKline Pharma GmbH & Co. KG, Hoffmann-La Roche AG Medical Affairs, Janssen-Cilag GmbH, Janssen Research Foundation, Knoll Deutschland GmbH, Lilly Deutschland GmbH Niederlassung Bad Homburg, Lundbeck GmbH & Co. KG, Novartis Pharma GmbH, Nordmark Arzneimittel GmbH, Organon GmbH, Otsuka-Pharma Frankfurt, Pfizer GmbH, Pharmacia & Upjohn GmbH, Promonta Lundbeck Arzneimittel, Recordati Pharma GmbH, Rhone-Poulenc Rohrer, Sanofi-Synthelabo GmbH, Sanofi-Aventis Deutschland, Schering AG, SmithKlineBeecham Pharma GmbH, Solvay Arzneimittel GmbH, Synthelabo Arzneimittel GmbH, Dr. Wilmar Schwabe GmbH & Co., Thiemann Arzneimittel GmbH, Troponwerke GmbH & Co. KG, Upjohn GmbH, Wander Pharma GmbH and Wyeth-Pharma GmbH. Austrian companies: Astra Zeneca \u00d6sterreich GmbH, Boehringer Ingelheim Austria, Bristol-Myers Squibb GmbH, CSC Pharmaceuticals GmbH, Eli Lilly GmbH, Germania Pharma GmbH, GlaxoSmithKline Pharma GmbH, Janssen-Cilag Pharma GmbH, Lundbeck GmbH, Novartis Pharma GmbH, Pfizer Med Inform and Wyeth Lederle Pharma GmbH. Swiss companies: AHP (Schweiz) AG, AstraZeneca AG, Bristol-Myers Squibb AG, Desitin Pharma GmbH, Eli Lilly (Suisse) S.A., Essex Chemie AG, GlaxoSmithKline AG, Janssen-Cilag AG, Lundbeck (Suisse) AG, Organon AG, Pfizer AG, Pharmacia, Sanofi-Aventis (Suisse) S.A., Sanofi-Synthelabo SA, Servier SA, SmithKlineBeecham AG, Solvay Pharma AG, Wyeth AHP (Suisse) AG and Wyeth Pharmaceuticals AG. BH, TG, MH, OZ, JE, RG, SB, PP, PP and MS declare no financial interest. Non-financial interests: BH, TG, MH, OZ, JE, PP, PP and MS declare no non-financial interest. SB, RG, and ST are project managers of the AMSP program.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The evaluated data were obtained from a completely anonymized database, ensuring that subjects could not be traced. Evaluations based on AMSP data were approved by the Ethics Committee of the University of Munich and the Ethics Committee of the Hannover Medical School (Nr. 8100_BO_S_2018).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}